Particular aspects of platinum compounds used at present in cancer treatment.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2002-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1040-8428(01)00219-0PMID 12050023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  2012cited by this paper
• Preclinical Perspectives on Platinum Resistance

  2012cited by this paper
• Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin

  2004cited by this paper
• Chemical reactivity of cisplatin bound to human plasma proteins

  2004cited by this paper
• Multicellular resistance: a paradigm for clinical resistance?

  2000cited by this paper
• Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

  2000influential reference
• Clinical pharmacokinetics of oxaliplatin: a critical review.

  2000cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999influential reference
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Single d(GpG)/cis-diammineplatinum(II) adduct-induced inhibition of DNA polymerization.

  1999cited by this paper
• Resistance to cisplatin.

  1999influential reference
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.

  1998cited by this paper
• Clinical studies of reversal of drug resistance based on glutathione.

  1998cited by this paper
• The role of DNA mismatch repair in drug resistance.

  1998cited by this paper
• Ongoing and unsaid on oxaliplatin: the hope.

  1998cited by this paper
• Cell culture as spheroids: an approach to multicellular resistance.

  1998cited by this paper
• Carboplatin versus cisplatin in solid tumors: an analysis of the literature.

  1998cited by this paper
• Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

  1998cited by this paper
• Oxaliplatin in practice.

  1998cited by this paper
• Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.

  1998cited by this paper
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.

  1997cited by this paper
• Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death.

  1997cited by this paper
• Evaluation of two dose individualisation methods for carboplatin.

  1996cited by this paper
• Relationship between Cell‐killing Efficiency and Number of Platinum Atoms Binding to DNA, RNA, and Protein Molecules in HeLa Cells Treated with cis‐Diamine(glycolato)platinum(II)

  1996cited by this paper
• Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump.

  1996cited by this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

  1996cited by this paper
• Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration.

  1996cited by this paper
• Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells

  1995cited by this paper
• Expression of bcl-xL can confer a multidrug resistance phenotype.

  1995cited by this paper
• Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

  1995cited by this paper
• Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma.

  1995cited by this paper
• DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo.

  1995cited by this paper
• Cisplatin and DNA repair in cancer chemotherapy.

  1995cited by this paper
• Individual dose adaptation of anticancer drugs.

  1994cited by this paper
• Anticancer drug resistance and inhibition of apoptosis.

  1994cited by this paper
• Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

  1994cited by this paper
• Comparison of two dose prediction models for cisplatin.

  1994cited by this paper
• Limited Sampling and Dose Prediction Model for Cisplatin Using a Bayesian Approach

  1994cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

  1993cited by this paper
• An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts.

  1992cited by this paper
• Mechanisms of resistance to cisplatin.

  1991cited by this paper
• Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

  1991cited by this paper
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

  1991cited by this paper
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  1991cited by this paper
• Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.

  1991cited by this paper
• Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

  1990cited by this paper
• Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II).

  1985cited by this paper
• Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.

  1984cited by this paper
• Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode

  1965cited by this paper

• Induction chemotherapy with nedaplatin, docetaxel and 5-fluorouracil followed by concurrent nedaplatin and radiotherapy in locoregionally advanced nasopharyngeal carcinoma: A single arm, open label, phase II clinical trial

  2026cites this paper
• Multi-Target Anticancer Activity of Structurally Diverse Schiff Bases: Insights into Cell-Cycle Arrest, DNA Damage, Metabolic Signaling, and Biomolecular Binding

  2026cites this paper
• Temporal and spatial distribution of Platinum Group Elements in rural French metropolitan territory using forest mosses.

  2025cites this paper
• Dysregulated Circular RNA and Long non-coding RNA-Mediated Regulatory Competing Endogenous RNA Networks (ceRNETs) in Ovarian and Cervical Cancers: A Non-coding RNA-Mediated Mechanism of Chemotherapeutic Resistance with New Emerging Clinical Capacities.

  2025cites this paper
• Platinum nanoparticles in cancer therapy: chemotherapeutic enhancement and ROS generation

  2025cites this paper
• Traditional and New Views on MSI-H/dMMR Endometrial Cancer

  2025cites this paper
• Copper oxide nanoparticles as delivery vehicles for different Pt(II)-drugs: experimental and theoretical evaluation.

  2025cites this paper
• Critical Review of Hearing Rehabilitation in Pediatric Oncology: Specific Considerations and Barriers

  2025cites this paper
• Thymoquinone Nanoparticles (TQ-NPs) in Kidney Toxicity Induced by Ehrlich Ascites Carcinoma (EAC): An In Vivo Study

  2024cites this paper
• 3-Aminobenzamide-linked multifunctional nanoparticles enhances anticancer activity of low-dose cisplatin chemotherapy in lung adenocarcinoma

  2024cites this paper
• Flow cytometer for a dilution-free measurement approach with sample recollection.

  2024cites this paper
• The Effects of Different Concentrations of Vitamin D3 on Immunological Parameters of Immunosuppressed Rats Induced

  2024cites this paper
• The Anti-proliferative Effect, Apoptotic Induction, and Cell Cycle Arrest of Tetra Halo Ruthenate Nanocomposites in Different Human Cancer Cell Lines

  2024cites this paper
• Core-Shell Iron Oxide-Platinium@Metal organic Framework/Epirubicin Nanospheres: Synthesis, Characterization and Anti-Breast Cancer Activity

  2023cites this paper
• Self-assembled amphiphilic bipyridine and bisquinoline cisplatin analogues: synthesis and anticancer properties

  2023cites this paper
• Vildagliptin restores cognitive function and mitigates hippocampal neuronal apoptosis in cisplatin-induced chemo-brain: Imperative roles of AMPK/Akt/CREB/ BDNF signaling cascades.

  2023cites this paper
• The Ameliorative Effect of Honey on Lead (Pb) – Induced Nephrotoxicity in Male Wistar Rats

  2023cites this paper
• Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance

  2023cites this paper
• Pomegranate Nanoparticle Mitigates Cisplatin-Induced testicular toxicity and Improves Cisplatin Anti-Cancer Efficacy in Ehrlich Carcinoma Model

  2023cites this paper
• Benzimidazole-Based NHC Metal Complexes as Anticancer Drug Candidates: Gold(I) vs. Platinum(II)

  2023cites this paper
• Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial.

  2023cites this paper
• Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin—A Review

  2023cites this paper
• Cleavage and Noncleavage Chemistry in Reactive Oxygen Species (ROS)-Responsive Materials for Smart Drug Delivery.

  2023cites this paper
• Two palladium (II) complexes derived from halogen-substituted Schiff bases and 2-picolylamine induce parthanatos-type cell death in sensitive and multi-drug resistant CCRF-CEM leukemia cells.

  2023cites this paper
• Graphene Oxide Enhanced Cisplatin Cytotoxic Effect in Glioblastoma and Cervical Cancer

  2023cites this paper
• The effects of cisplatin and jaceosidin on SH-SY5Y neuroblastoma cells: an electron microscopic, molecular and biochemical study

  2023cites this paper
• Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs

  2022cites this paper
• Time-Dependent Studies of Oxaliplatin and Other Nucleolar Stress-Inducing Pt(II) Derivatives.

  2022cites this paper
• Self-therapeutic metal-based nanoparticles for treating inflammatory diseases

  2022cites this paper
• DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?

  2022cites this paper
• Synthesis, spectral, antioxidant, in vitro cytotoxicity activity and thermal analysis of Schiff base metal complexes with 2,2′-Bipyridine-4,4′-dicarboxylic acid as co-ligand

  2022cites this paper
• RALY regulate the proliferation and expression of immune/inflammatory response genes via alternative splicing of FOS

  2022cites this paper
• Synthesis, characterization, antitumor potential, and investigation of mechanism of action of copper(ii) complexes with acylpyruvates as ligands: interactions with biomolecules and kinetic study

  2022cites this paper
• Novel Pomegranate-Nanoparticles Ameliorate Cisplatin-Induced Nephrotoxicity and Improves Cisplatin Anti-Cancer Efficacy in Ehrlich Carcinoma Mice Model

  2022cites this paper
• Detailed structural and spectroscopic elucidation of ferrocenium coupled N-heterocyclic carbene gold(I) complexes.

  2022cites this paper
• Berberis integerrima hydro-alcoholic root extract ant its constituent berberine protect against cisplatin-induced nephro- and hepato-toxicity.

  2022cites this paper
• The assessment of physicochemical properties of Cisplatin complexes with purines and vitamins B group.

  2022cites this paper
• Anti-Cancer Effect of Bromelain and Its Combination with Cisplatin on HN5 Cell Line (Squamous Cell Carcinoma)

  2022cites this paper
• Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100

  2022cites this paper
• Second and third-row transition metal compounds containing benzimidazole ligands: An overview of their anticancer and antitumour activity

  2022cites this paper
• Crystal Structures of Half-Sandwich Ru(II) Complexes, [(η6-p-Cymene)(3-chloro-6-(1H-pyrazol-1-yl)pyridazine)Ru(X)]BF4, (X = Cl, Br, I)

  2022cites this paper
• TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis

  2022cites this paper
• Cisplatin in Cancer Treatment.

  2022cites this paper
• Treatment of clinical stage I non-seminoma

  2021cites this paper
• Antitumor Effects of Dihydromyricetin on the Proliferation, Migration and Apoptosis of Human Hepatocellular Carcinoma Hep3B Cells

  2021cites this paper
• Distribution of platinum (Pt), palladium (Pd), and rhodium (Rh) in urban tributaries of the Scheldt River assessed by diffusive gradients in thin films technique (DGT).

  2021cites this paper
• Interference between copper transport systems and platinum drugs.

  2021cites this paper
• Tracing the anticancer compound [RuII(η6-p-cymene)(8-oxyquinolinato)Cl] in a biological environment by mass spectrometric methods.

  2021cites this paper
• Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.

  2021cites this paper
• DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death

  2021cites this paper
• Investigation The Quantum Chemical Parameters and Electronic Transition States for Suggested Platinum Metal Complex

  2021cites this paper
• Alteration of Oxidative stress and apoptotic markers alterations in the rat prefrontal cortex influence behavioral response induced by cisplatin and N-acetylcysteine in the tail suspension test.

  2021cites this paper
• Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.

  2021cites this paper
• Hearing Loss Risk in Pediatric Patients Treated with Cranial Irradiation and Cisplatin-Based Chemotherapy.

  2021cites this paper
• Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity.

  2021cites this paper
• RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway

  2021cites this paper
• Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy

  2021cites this paper
• Acacia hydaspica R. Parker ethyl-acetate extract abrogates cisplatin-induced nephrotoxicity by targeting ROS and inflammatory cytokines

  2021cites this paper
• The Synergistic Combination of Cisplatin and Piperine Induces Apoptosis in MCF-7 Cell Line

  2021cites this paper
• Anticancer effects of dihydromyricetin on the proliferation, migration, apoptosis and in vivo tumorigenicity of human hepatocellular carcinoma Hep3B cells

  2021cites this paper
• Towards Imaging Pt Chemoresistance Using Gd(III)‐Pt(II) Theranostic MR Contrast Agents

  2021cites this paper
• Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter

  2020cites this paper
• Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads

  2020cites this paper
• Exploring the DNA Binding Mechanisms of Platinum-Based Chemotherapeutic Agents: State of Art and Perspectives of the Candidates

  2020cites this paper
• Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

  2020cites this paper
• Immuno-Histochemical Study of the Potential Impact Effect of a Single Intra-Peritoneal Injection Dose of Cisplatin on Stem Cells of Dental Pulp of Albino Rats

  2020cites this paper
• Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity

  2020cites this paper
• Mechanistic perspective of protective effects of nilotinib against cisplatin-induced testicular injury in rats: Role of JNK/caspase-3 signaling inhibition.

  2020cites this paper
• SH003 activates autophagic cell death by activating ATF4 and inhibiting G9a under hypoxia in gastric cancer cells

  2020cites this paper
• Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status

  2020cites this paper
• The effect of some natural antioxidants against cisplatin-induced neurotoxicity in rats: behavioral testing

  2020cites this paper
• References

  2020cites this paper
• Attenuation of cisplatin-induced acute kidney injury by N-(2-Hydroxyphenyl) acetamide and its gold conjugated nano-formulations in mice.

  2020cites this paper
• EFFECT OF VARIABLE DOSES OF CISPLATIN ON MICROANATOMY OF TESTIS IN ALBINO RATS

  2020cites this paper
• Phytochemicals and Cytotoxicity of Quercus infectoria Ethyl Acetate Extracts on Human Cancer Cells

  2020cites this paper
• Bioavailability and Modes of Action of Novel Metal Based Phenanthroline Drugs

  2020cites this paper
• Highly conjugative heterocyclic nitrogen base derivative and its metal complexes towards optoelectronic materials: Chemical architecture, synthesis, structural elucidation, catalytic, optoelectronic and pharmacological studies

  2020cites this paper
• ESI MS studies highlight the selective interaction of Auranofin with protein free thiols.

  2020cites this paper
• One‐Pot Synthesis of New Organometallic Compounds with Platinum‐Carbon Bond

  2020cites this paper
• Cytotoxic effect of anise seed (Pimpinella anisum) extract on KB cell line – a comparative study with CISPLATIN

  2020cites this paper
• Gd(iii)–Pt(iv) theranostic contrast agents for tandem MR imaging and chemotherapy†

  2020cites this paper
• Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies.

  2020cites this paper
• Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903

  2020cites this paper
• Ameliorative Effect of Camel Urotherapy to Cisplatin Induced Urinary Tract Subacute and Chronic Toxicity in Male Albino Rats

  2020cites this paper
• Comparative nephroprotective effects of curcumin and etoricoxib against cisplatin-induced acute kidney injury in rats.

  2020cites this paper
• Cancer treatment drugs and endocrine-disrupting chemicals release and fate in hospital wastewater

  2020cites this paper
• Transcriptomic Landscape of Cisplatin-Resistant Neuroblastoma Cells

  2019cites this paper
• GAMBARAN HISTOPATOLOGI HEPAR DENGAN INDUKSI CISPLATIN DAN EKSTRAK DAUN BANGUN-BANGUN (Coleus amboinicus) PADA TIKUS WISTAR (Rattus novergicus)

  2019cites this paper
• Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It

  2019cites this paper
• NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.

  2019cites this paper
• Prophylactic Effect of Butea monosperma against Cisplatin-Induced Nephrotoxicity in Rats

  2019cites this paper
• ASSESSMENT OF ‘CYTOTHREAT’ OF THREE CHEMOTHERAPEUTIC DRUGS USING ALLIUM TEST AND ITS AMELIORATION BY AQUEOUS PLANT EXTRACTS

  2019cites this paper
• Synthesis, characterization and evaluation of multi sensitive nanocarriers by using the layer by layer method

  2019cites this paper
• Docking of Cisplatin on Fullerene Derivatives and Some Cube Rhombellane Functionalized Homeomorphs

  2019cites this paper
• Evaluating the protective potency of Acacia hydaspica R. Parker on histological and biochemical changes induced by Cisplatin in the cardiac tissue of rats

  2019cites this paper
• Design and synthesis of novel pyrazolone based coordination compounds: DNA synergy, biological screening, apoptosis, molecular docking and in-silico ADMET profile

  2019cites this paper
• Three Pt-Pt Complexes with Donor-Acceptor Feature: Anticancer Activity, DNA Binding Studies and Molecular Docking Simulation.

  2019cites this paper
• Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics

  2019cites this paper
• MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.

  2019cites this paper
• Drug Management Pattern and Their Adverse Effects in Patients of Cervical Carcinoma Attending Two Tertiary Care Hospitals in Dhaka City

  2019cites this paper